HOPKINTON, Mass. and TOKYO, April 30,
2024 /PRNewswire/ -- Phosphorex, an Ampersand
Capital Partners company and drug delivery-focused contract
development and manufacturing organization ("CDMO"), announced
today a collaboration with NOF CORPORATION to supply its
global clients with NOF's COATSOME® SS Series
proprietary ionizable lipids, further enhancing its leading
position in providing lipid nanoparticle (LNP)-based drug delivery
solutions to the market.
NOF CORPORATION's COATSOME® SS Series offers
encapsulation of nucleic acids such as mRNA, siRNA, and pDNA. These
proprietary ionizable lipids offer efficient drug delivery into the
cytoplasm of cells with higher biodegradability and low toxicity,
with controlled targeting to organs such as the liver, spleen, and
lymph nodes.
"The combination of NOF's lipid technologies and Phosphorex's
experience in developing and scaling LNP-based drug delivery
solutions delivers a faster, more cost effective and reproducible
outcome for customers," said Jarlath
Keating, CEO of Phosphorex. "This integrated approach,
combining lipid chemistries with state-of-the-art development and
manufacturing processes provides a well characterized platform for
customers developing LNP-based therapies."
"This collaboration strengthens both companies' portfolios and
industry presence by incorporating LNP material development,
formulation development and manufacturing services delivering a
comprehensive solution to its combined customer base. With this
collaboration NOF and Phosphorex create a highly specialized
LNP-focused CDMO with unique capabilities," said Yuji Yamamoto, General Manager of Life Science
division of NOF CORPORATION.
About Phosphorex
Phosphorex is a leading provider of
drug delivery technologies and solutions. By harnessing the
potential of microspheres and nanoparticles for drug delivery,
Phosphorex offers tailored solutions and enabling technologies to
optimize a drug's release rate, targeting ability, bioavailability,
and deliverability, with the goal of achieving desired therapeutic
effects while reducing adverse clinical outcomes. Phosphorex
supports pharmaceutical and biotech companies through all phases of
their development, from proof of concept to clinical studies.
Phosphorex's mission is to help our partners solve complex problems
and develop successful drugs to help patients. Additional
information about Phosphorex is available at www.phosphorex.com or
follow us on LinkedIn.
About Ampersand Capital Partners
Founded in 1988,
Ampersand Capital Partners is a middle market private equity firm
with $3 billion of assets under
management dedicated to growth-oriented investments in the
healthcare sector. With offices in Boston, MA and Amsterdam, Netherlands, Ampersand leverages a
unique blend of private equity and operating experience to build
value and drive long-term performance alongside its portfolio
company management teams. Ampersand has helped build numerous
market-leading companies across each of the firm's core healthcare
sectors. For additional information, visit www.ampersandcapital.com
or follow us on LinkedIn.
About NOF CORPORATION
The NOF Group pursues
multi-faceted business development in five divisions of activities
based on its own technologies. Since 2001, DDS Development
Division is organized within NOF's family of complementary business
units, offering innovation to pharmaceutical and biomedical
products. In April 2023, the DDS
Development Division was renamed the Life Science Division and will
continue to contribute to the pharmaceutical and medical fields.
NOF supplies high-purity phospholipids, diacylglycerol PEGs
and proprietary ionizable lipids as materials for LNP. For
additional information, visit www.nof.co.jp/english/business/life
and dds-drug.com or follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phosphorex-and-nof-corporation-collaborate-to-supply-lipid-nanoparticle-formulations-using-nofs-proprietary-ionizable-lipid-coatsome-ss-series-302131678.html
SOURCE Phosphorex